Caris Life Sciences, Inc. (CAI) fair value analysis
Nasdaq · Updated 2026-10-19
CAI price how computed
Valuation status
Awaiting full valuationCAI's estimate rests on a sector-average price-to-earnings multiple, not on its own validated earnings history.
TickrTrends does not publish a borrowed multiple as a verdict. A verdict publishes automatically once CAI's own trailing P/E history validates; every covered stock is re-evaluated weekly.
- Last price
- $30.56
- Sector
- Healthcare
- 12-month range
- $14.55–$32.27
- Market cap
- $8.64B
- From 52-week high
- -5.3%
- Shares outstanding
- 283M
- Rank in Healthcare by quality score
- #24 of 301
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
Caris Life Sciences is a healthcare company that provides molecular profiling and diagnostic testing services designed to help physicians personalize cancer treatment decisions. The company operates in the United States and serves patients through its laboratory and clinical network.
CAI currently ranks #24 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $8.64B
- P/E (trailing)
- n/m
- Revenue (TTM)
- $990M
- Net margin
- 10.6%
- EPS (TTM)
- $-0.18
- Gross margin
- 68.1%
- Debt / equity
- 0.76
- Revenue growth (3-yr avg)
- 69.2%
- Shares outstanding
- 283M
Derived indicators how computed
- Quality grade
- A
- Margin trend
- Expanding
- 52-week position
- The top quarter of its range
Technicals how computed
- RSI (14-day)
- 51 · neutral
- 50-day average
- $27.07
- 200-day average
- $21.29
- Moving-average state
- 50-day above 200-day (golden cross state); price above both averages
Earnings how computed
- Next earnings report
- 2026-11-04 (post-market)
- Last 6 quarters vs consensus
- 3 beat, 3 missed
- Quarter by quarter
- 2026-06 ▼ miss (-5300.0%)
2026-03 ▲ beat (+91.0%)
2025-12 ▲ beat (+2700.0%)
2025-09 ▲ beat (+200.0%)
2025-06 ▼ miss (-404.5%)
2025-03 ▼ miss
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 10 buy · 4 hold · 0 sell (14 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $31.6
- Target vs last price
- +3.4%
What our data shows for CAI
- Shares are trading in the upper third of their 12-month price range of $14.55–$32.27.
- The 14-day relative strength index sits at a neutral 51.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- CAI's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the CAI conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends' derived indicators for CAI showed a shift in momentum this week as the RSI zone moved from overbought to neutral territory, suggesting a moderation in the stock's recent strength relative to its recent price history. The valuation verdict remains in an awaiting full valuation status, indicating that comprehensive valuation analysis is still pending.
- 2026-09-21 — TickrTrends' derived indicators for CAI show that the 50/200-day trend state shifted from mixed to uptrend this week, while the RSI zone moved from neutral to overbought. The stock's current valuation verdict remains awaiting full valuation. These technical changes suggest increased upward momentum in the Healthcare sector stock.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is CAI stock undervalued?
CAI's estimate rests on a sector-average price-to-earnings multiple rather than its own validated earnings history, and TickrTrends does not publish a borrowed multiple as a verdict. It is re-evaluated every week.
What is CAI's TickrTrends verdict?
CAI is currently marked 'Awaiting full valuation' - a verdict publishes automatically once CAI's own trailing P/E history validates under our standards.
How does CAI compare to other Healthcare stocks?
CAI ranks #24 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is CAI overbought or oversold?
CAI's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does CAI report earnings next?
CAI's next earnings report is scheduled for 2026-11-04 (post-market), per the published earnings calendar.
Does CAI usually beat earnings estimates?
Over its last 6 reported quarters CAI beat the consensus estimate 3 times and missed 3 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about CAI?
Of 14 analysts covering CAI, 10 rate it a buy, 4 a hold and 0 a sell - buy-leaning, with a consensus price target of $31.6 (+3.4% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.